For the best user experience please use a browser to proceed.

MYGN - Myriad Genetics, Inc price and analysis

Fundamentals:
Basic Info:
  • Market Cap: 2.45B
  • Exchange: NASDAQ
  • Shares Float: 75,296,000
  • Shares Outstanding: 77,052,000
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -23.50 %
  • ROA ttm: -7.65 %
  • Beta: 1.637
  • EPS: 0.06
  • Debt Ratio ttm: 0.35
  • Debt / Equity Ratio ttm: 0.53
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 1
  • Current Ratio ttm: 2.21
  • Quick Ratio ttm: 1.83
Key Ratios:
  • P/E trailing 12 month: -15.9
  • P/E forward: 555.82
  • P/E trailing 12m high: -5.65
  • P/E trailing 12m low: -16.99
  • P/S trailing 12 month: 4.33
  • EV/S trailing 12 month: 4.48
  • P/B trailing 12 month: 2.8
  • PEG ratio: 1.4
Shorts:
  • Shares Short: 5,327,700
  • Shares Short Prev Month: 5,374,100
  • Days to Cover: 9.46
  • Short Percent Float: 7.08 %
  • Short Percent Outstanding: 7.00 %
Ownership:
  • Percent Insiders: 1.70 %
  • Percent Institutions: 99.33 %
Margins:
  • Gross Profit Margin ttm: 69.00 %
  • EBITDA Margin ttm: 3.00 %
  • Operating Margin ttm: -28.90 %
  • Net Income Margin ttm: -27.00 %
Target Prices:
  • Target Price High: 37 USD
  • Target Price Low: 14 USD
  • Target Price Mean: 26.63 USD
  • Number of Analysts: 8
Key Prices:
  • 52 Week High: 34.02
  • 52 Week Low: 11.32
  • 50 Day Moving Average: 30.87
  • 200 Day Moving Average: 29.07
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.27 ~ -0.02 (2021-06-30)
  • Current Quarter revenue estimate: 151.40M ~ 175.30M
  • Median revenue growth YoY estimate: 75.27%
As of: 2021-07-25
Latest News:
Myriad Genetics Supports New ACMG Recommendation StatementGlobeNewswire2021-07-21 20:05:00 EDT
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core UnitsZacks Investment Research2021-07-02 08:16:07 EDT
Myriad Genetics (MYGN) Sells myPath to Focus on Core UnitsZacks Investment Research2021-06-02 11:17:06 EDT
Myriad Genetics' (MYGN) GeneSight Test Rollout Initiated by IPMZacks Investment Research2021-05-31 08:16:03 EDT
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research2021-05-03 19:34:08 EDT
3 Women Healthcare Stocks With Solid Growth Potential Amid COVID-19Zacks Investment Research2021-04-09 09:50:11 EDT
Myriad Genetics' (MYGN) myChoice Gets Additional ReimbursementZacks Investment Research2021-03-29 10:36:07 EDT
Myriad Genetics (MYGN) Collaborates to Advance Oncology CareZacks Investment Research2021-03-05 10:40:09 EDT
Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in LineZacks Investment Research2021-02-24 10:37:16 EDT
Myriad Genetics (MYGN) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research2021-02-23 18:55:23 EDT
Recap: Myriad Genetics Q2 EarningsBenzinga2021-02-23 17:10:32 EDT
Myriad Genetics' (MYGN) Prolaris Test Study Outcome FavorableZacks Investment Research2021-02-15 16:03:53 EDT
MYGN: What does Argus have to say about MYGN?Yahoo Finance2021-02-10 00:01:00 EDT
Myriad Genetics Inc Ordinary Shares MYGNMorningstar%2c Inc.2021-02-08 00:00:00 EDT
Myriad Genetics Inc MYDMorningstar%2c Inc.2021-01-29 00:00:00 EDT
MYGN: Raising target price to $22.00Yahoo Finance2021-01-20 00:00:00 EDT
MYGN Jan 2021 8.000 callYahoo Finance2021-01-14 17:11:00 EDT
MYGN Jan 2021 12.000 callYahoo Finance2021-01-14 15:19:00 EDT
MYGN Jan 2021 22.000 putYahoo Finance2021-01-14 15:08:00 EDT
Click to expand the area.
Income Statements:
MYGN - Myriad Genetics, Inc Income Statement
Unit: (milllion)2018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1
Qtr Revenue194.90202.30216.80216.60215.40186.30195.10164.0093.20145.20154.60173.10
Rev Growth yoy-2.79 %6.36 %11.75 %11.94 %10.52 %-7.91 %-10.01 %-24.28 %-56.73 %-22.06 %-20.76 %5.55 %
Cost of Revenue45.8049.7052.1048.6050.6049.7049.6050.1036.7044.2047.1050.30
Gross Profit149.10152.60164.70168.00164.80136.60145.50113.9056.50101.00107.50122.80
Gross Profit Mgn76.5 %75.43 %75.97 %77.56 %76.51 %73.32 %74.58 %69.45 %60.62 %69.56 %69.53 %70.94 %
Research and Development17.7021.1022.4021.5020.9021.3018.8019.7017.4017.6018.2023.10
Selling & Marketing Expense0.000.000.000.000.000.000.000.000.000.000.000.00
General & Administrative Expense121.60129.90135.20140.60149.80135.50135.60132.90107.40124.100.000.00
Interest Expense1.002.203.403.203.202.902.502.303.102.902.903.00
Operating Expense139.30151.00157.60162.10170.70156.80154.40152.60124.80141.70151.10168.60
Operating Income9.801.607.105.90-5.90-20.20-8.90-38.70-68.30-40.70-43.60-45.80
Operating Mgn5.03 %0.79 %3.27 %2.72 %-2.74 %-10.84 %-4.56 %-23.6 %-73.28 %-28.03 %-28.2 %-26.46 %
Net Income6.50-0.702.606.90-4.20-20.60-8.30-115.20-55.40-15.20-44.20-39.50
Net Income Mgn3.34 %-0.35 %1.2 %3.19 %-1.95 %-11.06 %-4.25 %-70.24 %-59.44 %-10.47 %-28.59 %-22.82 %
Generated by @earningsfly with ❤️
Cashflow Statements:
MYGN - Myriad Genetics, Inc Cashflow Statement
Unit: (million)2018Q22018Q32018Q42019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q42021Q1
Operating Cashflows47.907.8037.806.6031.5015.80-1.9016.8030.00-59.30-13.7071.80
Financing Cashflows-41.30252.10-32.60-9.40-27.80-12.301.100.201.00-3.90NaN-48.50
Investing Cashflows8.90-279.00-8.10-3.804.50-7.10-7.2023.2010.3017.10NaN8.20
Total Capital Expenditures1.801.302.803.101.401.403.403.002.401.50-6.707.10
Changes In Cash13.50-17.60-2.70-5.708.30-3.301.60-108.50-55.50-46.10NaN31.50
Free Cash flow46.106.5035.003.5030.1014.40-5.3013.8027.60-60.80-20.4064.70
Generated by @earningsfly with love ❤️
Balance Sheets:
MYGN - Myriad Genetics, Inc Balance Sheet
Unit: (milllion)2021Q1
Total Assets1336.90
Intangible Assets888.20
Goodwill328.30
Current Assets329.20
Current Cash148.90
Account Receivables96.50
Inventory24.60
Total Liabilities461.70
Account Payables20.80
Short Term Debt0.00
Long Term Debt154.00
Current Ratio2.21
Debt Ratio0.12
Debt/Equity Ratio0.18
Generated by @earningsfly with ❤️
Latest Posts:
Not available at this time..
Myriad Genetics, Inc
(NASDAQ:MYGN)
Myriad Genetics, Inc

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA seq...
Sector: Healthcare
Industry: Diagnostics & Research
Full Time Employees: 2,700
Next Earnings Date: 2021-08-12
Keywords: myriad genetics
Summary and stock analysis:
  • Return on equity score:
  • Return on assets score:
  • P/E ratio score:
  • P/B ratio score:
  • P/S ratio score:
  • Revenue growth score:
5.2K Followers
627 Followers
Avg: 
 185 review, 200 jobs
Basic Info:
  • Market Cap: 2.45B
  • Exchange: NASDAQ
  • Shares Float: 75,296,000
  • Shares Outstanding: 77,052,000
  • Revenue Per Employee:
Advanced Info:
  • ROE ttm: -23.50 %
  • ROA ttm: -7.65 %
  • Beta: 1.637
  • EPS: 0.06
  • Debt Ratio ttm: 0.35
  • Debt / Equity Ratio ttm: 0.53
  • Payout Ratio ttm:
Cash Ratios:
  • Cash Ratio ttm: 1
  • Current Ratio ttm: 2.21
  • Quick Ratio ttm: 1.83
Key Ratios:
  • P/E trailing 12 month: -15.9
  • P/E forward: 555.82
  • P/E trailing 12m high: -5.65
  • P/E trailing 12m low: -16.99
  • P/S trailing 12 month: 4.33
  • EV/S trailing 12 month: 4.48
  • P/B trailing 12 month: 2.8
  • PEG ratio: 1.4
Shorts:
  • Shares Short: 5,327,700
  • Shares Short Prev Month: 5,374,100
  • Days to Cover: 9.46
  • Short Percent Float: 7.08 %
  • Short Percent Outstanding: 7.00 %
Ownership:
  • Percent Insiders: 1.70 %
  • Percent Institutions: 99.33 %
Margins:
  • Gross Profit Margin ttm: 69.00 %
  • EBITDA Margin ttm: 3.00 %
  • Operating Margin ttm: -28.90 %
  • Net Income Margin ttm: -27.00 %
Target Prices:
  • Target Price High: 37 USD
  • Target Price Low: 14 USD
  • Target Price Mean: 26.63 USD
  • Number of Analysts: 8
Key Prices:
  • 52 Week High: 34.02
  • 52 Week Low: 11.32
  • 50 Day Moving Average: 30.87
  • 200 Day Moving Average: 29.07
Dividends:
  • Trailing Dividend yld:
  • Forward Dividend yld:
  • Payout Ratio:
  • Ex-Dividend date: None
Current Quarter Estimates:
  • Current Quarter EPS estimate: -0.27 ~ -0.02 (2021-06-30)
  • Current Quarter revenue estimate: 151.40M ~ 175.30M
  • Median revenue growth YoY estimate: 75.27%
As of: 2021-07-25
Click to expand the area.
Analyst Consensus:
MYGN - Myriad Genetics, Inc Analyst Opinions
Target high: 37 USD
Target low: 14 USD
Average: 26.63 USD based on 8 analysts as of 2021-07-03

Generated by @earningsfly with ❤️
Analyst Trends:
MYGN - Myriad Genetics, Inc Analyst Trends
Target high: 37 USD
Target low: 14 USD
Average: 26.63 USD based on 8 analysts as of 2021-07-03
Generated by @earningsfly with ❤️
Website Ranking Analysis:
MYGN - Myriad Genetics, Inc  World Website Ranking Analysis
Generated by @earningsfly with ❤️
Google Trends Analysis:
MYGN - Myriad Genetics, Inc Google 5-year Trends Analysis
Keyword: Myriad Genetics
Generated by @earningsfly with ❤️
Employees Analysis:
MYGN - Myriad Genetics, Inc Employees Analysis
Generated by @earningsfly with ❤️
Institution & Insiders Analysis:
MYGN - Myriad Genetics, Inc Ownership Analysis
Generated by @earningsfly with ❤️
Debt & Cash Analysis:
MYGN - Myriad Genetics, Inc Cash and Debt Analysis(unit: milllion USD)
Generated by @earningsfly with ❤️
Short Analysis:
MYGN - Myriad Genetics, Inc Shorts Analysis
Generated by @earningsfly with 🚀
Margins and Revenue:
MYGN - Myriad Genetics, Inc Revenue and Margins
Generated by @earningsfly with 🚀
Income Statement Analysis:
MYGN - Myriad Genetics, Inc Income Statement
Unit: (milllion)2020Q22020Q32020Q42021Q1
Qtr Revenue93.20145.20154.60173.10
Rev Growth yoy-56.73 %-22.06 %-20.76 %5.55 %
Cost of Revenue36.7044.2047.1050.30
Gross Profit56.50101.00107.50122.80
Gross Profit Mgn60.62 %69.56 %69.53 %70.94 %
Research and Development17.4017.6018.2023.10
Selling & Marketing Expense0.000.000.000.00
General & Administrative Expense107.40124.100.000.00
Interest Expense3.102.902.903.00
Operating Expense124.80141.70151.10168.60
Operating Income-68.30-40.70-43.60-45.80
Operating Mgn-73.28 %-28.03 %-28.2 %-26.46 %
Net Income-55.40-15.20-44.20-39.50
Net Income Mgn-59.44 %-10.47 %-28.59 %-22.82 %
Generated by @earningsfly with ❤️
Earnings Estimate Analysis:
MYGN - Myriad Genetics, Inc EPS Estimates
Current Qtr Estimate (dashed line): -0.09
Generated by @earningsfly with ❤️
Cashflow Analysis:
MYGN - Myriad Genetics, Inc Cashflow Statement
Unit: (million)2020Q22020Q32020Q42021Q1
Operating Cashflows30.00-59.30-13.7071.80
Financing Cashflows1.00-3.90NaN-48.50
Investing Cashflows10.3017.10NaN8.20
Total Capital Expenditures2.401.50-6.707.10
Changes In Cash-55.50-46.10NaN31.50
Free Cash flow27.60-60.80-20.4064.70
Generated by @earningsfly with love ❤️